| Title |
Neuro-rejuvenation for neuronal function
|
|---|---|
| Published in |
Neural Regeneration Research, January 2016
|
| DOI | 10.4103/1673-5374.193226 |
| Pubmed ID | |
| Authors | |
| Abstract |
Neurodegenerative eye diseases, such as glaucoma, cause irreversible vision loss in millions of patients worldwide, creating serious medical, economic and social issues. Like other mammalian central nervous system tracts, optic nerve intrinsically lacks the capacity for axonal growth and its surrounding environment is also non-permissive to regeneration. Any axonal damage also triggers a vicious cycle of retinal ganglion cell (RGC) death. Exploring methods that can enhance RGCs survival and promote axonal regeneration will not only enable vision restoration for millions of patients, but also shed light on the treatment of other neurodegenerative diseases. In this review article, we will go through three current approaches to cure neurodegenerative eye diseases, including cell based therapy, neuro-regeneration and neuro-rejuvenation. |
Login to access the Attention Digest and the Sentiment Analysis related to this output.
X Demographics
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 100% |
Mendeley demographics
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 25 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 6 | 24% |
| Researcher | 4 | 16% |
| Other | 2 | 8% |
| Student > Doctoral Student | 2 | 8% |
| Student > Bachelor | 1 | 4% |
| Other | 2 | 8% |
| Unknown | 8 | 32% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 3 | 12% |
| Biochemistry, Genetics and Molecular Biology | 2 | 8% |
| Neuroscience | 2 | 8% |
| Pharmacology, Toxicology and Pharmaceutical Science | 1 | 4% |
| Agricultural and Biological Sciences | 1 | 4% |
| Other | 4 | 16% |
| Unknown | 12 | 48% |